The present study demonstrated that ascorbic acid enhances the efficacy of immunotherapy and that the loss of TET2 function enables RCC cells to evade antitumor immunity and resist anti-PD-L1 therapy. The gene discussed is CD274; the disease is renal cell carcinoma.